Inspire Medical Systems Reports Q1 Loss and Lowers 2026 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Inspire Medical Systems Inc. experienced a significant decline in its stock price, hitting a 52-week low, following the announcement of a net loss of $11.29 million for Q1 2026, which translates to a loss of $0.39 per share. This stark contrast to last year's net income of $2.99 million raised concerns among investors about the company's financial health.
The company also lowered its revenue guidance for 2026 to between $825 million and $875 million, down from previous expectations of $950 million to $1 billion. This revision reflects the adverse impacts from reimbursement and CPT coding disruptions, leading to a more pessimistic outlook for the company's future. The market reacted negatively, with the stock plummeting over 22% in pre-market trading, indicating diminished confidence in management's outlook.
The implications of these developments are significant, as the lowered guidance and reported losses may lead to further scrutiny from investors and analysts. The company must address the challenges posed by reimbursement processes and coding uncertainties to regain investor trust and stabilize its stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise
19 Analyst Rating
13 Buy
6 Hold
0 Sell
Moderate Buy
Current: 41.120
Low
91.00
Averages
145.31
High
180.00
Current: 41.120
Low
91.00
Averages
145.31
High
180.00
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inspire Medical Systems to Participate in Wells Fargo MedTech Innovation Spotlight
- Management Participation: Inspire Medical Systems' management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on June 26, 2026, showcasing its innovative solutions for obstructive sleep apnea, which is expected to attract investor and industry attention.
- Live Presentation Schedule: Inspire is scheduled to present at 10:00 a.m. Eastern Time, with the presentation accessible via a live webcast, enhancing the company's visibility in the medical technology sector to a global audience.
- Replay Availability: A replay of the presentation will be available for two weeks in the Event Archive section of Inspire's investor website, ensuring that investors who cannot attend live can access key information, thereby enhancing information transparency.
- Introduction of Innovative Technology: Inspire's proprietary therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology aimed at providing safe and effective treatment for moderate to severe obstructive sleep apnea patients, further solidifying its market leadership position.
See More
Investment Analysis of Healthcare Device Players
- Alphatec Growth Momentum: Alphatec's revenue for FY 2025 reached approximately $764.2 million, reflecting a 25% increase, despite a net loss of about $143.4 million; however, its net margin improved from -26.5% to -18.8%, indicating growing market acceptance in spine surgery.
- Inspire's Profitability Improvement: Inspire Medical Systems achieved revenue of around $912 million in FY 2025, a 13.6% increase, and successfully transitioned to profitability with a net income of approximately $145.4 million, raising its net margin from 6.7% to 15.9%, solidifying its leadership in advanced respiratory care.
- Competitive Landscape Analysis: Alphatec faces intense competition from giants like Medtronic and Johnson & Johnson, relying on a limited number of suppliers, which may expose it to pricing pressures from hospital consolidations, while Inspire's dependence on its single product makes it vulnerable to shifts in market demand.
- Valuation Comparison: Alphatec has a forward P/E of 25.8x and a P/S ratio of 1.7x, while Inspire's forward P/E is significantly higher at 47.0x with a P/S ratio of 1.3x, highlighting notable differences in market valuations that investors should consider based on their risk preferences.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
BofA Downgrades Inspire Medical to Underperform Amid Coding Concerns
- Rating Downgrade: Bank of America downgraded Inspire Medical Systems (INSP) from Neutral to Underperform, primarily due to the absence of a clear coding pathway for reimbursement of its Inspire V implant for sleep apnea, leading to decreased market confidence.
- Revenue Forecast Reduction: Analyst Travis Steed noted that Inspire has already cut its 2026 revenue guidance, projecting growth for 2027; however, the lack of an official code has led to lowered revenue and EPS estimates for 2027 and 2028, reflecting a pessimistic outlook on the company's future.
- Price Target Cut: BofA slashed Inspire's stock price target from $53 to $39, indicating concerns over the company's future profitability, especially given the significant risks associated with the absence of a stable coding pathway.
- Market Reaction: Following BofA's downgrade, Inspire's stock fell in premarket trading, reflecting investor concerns about the company's outlook, particularly with the potential delay in obtaining official coding until 2028 or later.
See More
Inspire Medical Systems to Participate in Wells Fargo MedTech Innovation Spotlight
- Management Participation: Inspire Medical Systems' management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on June 26, 2026, showcasing its innovative solutions for obstructive sleep apnea, which is expected to attract investor and industry attention.
- Live Presentation Schedule: Inspire is scheduled to present at 10:00 a.m. Eastern Time, with the presentation accessible via a live webcast, enhancing the company's visibility in the medical technology sector to a global audience.
- Replay Availability: A replay of the presentation will be available for two weeks in the Event Archive section of Inspire's investor website, ensuring that investors who cannot attend live can access key information, thereby enhancing information transparency.
- Introduction of Innovative Technology: Inspire's proprietary therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology aimed at providing safe and effective treatment for moderate to severe obstructive sleep apnea patients, further solidifying its market leadership position.
See More
Investment Analysis of Healthcare Device Players
- Alphatec Growth Momentum: Alphatec's revenue for FY 2025 reached approximately $764.2 million, reflecting a 25% increase, despite a net loss of about $143.4 million; however, its net margin improved from -26.5% to -18.8%, indicating growing market acceptance in spine surgery.
- Inspire's Profitability Improvement: Inspire Medical Systems achieved revenue of around $912 million in FY 2025, a 13.6% increase, and successfully transitioned to profitability with a net income of approximately $145.4 million, raising its net margin from 6.7% to 15.9%, solidifying its leadership in advanced respiratory care.
- Competitive Landscape Analysis: Alphatec faces intense competition from giants like Medtronic and Johnson & Johnson, relying on a limited number of suppliers, which may expose it to pricing pressures from hospital consolidations, while Inspire's dependence on its single product makes it vulnerable to shifts in market demand.
- Valuation Comparison: Alphatec has a forward P/E of 25.8x and a P/S ratio of 1.7x, while Inspire's forward P/E is significantly higher at 47.0x with a P/S ratio of 1.3x, highlighting notable differences in market valuations that investors should consider based on their risk preferences.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
BofA Downgrades Inspire Medical to Underperform Amid Coding Concerns
- Rating Downgrade: Bank of America downgraded Inspire Medical Systems (INSP) from Neutral to Underperform, primarily due to the absence of a clear coding pathway for reimbursement of its Inspire V implant for sleep apnea, leading to decreased market confidence.
- Revenue Forecast Reduction: Analyst Travis Steed noted that Inspire has already cut its 2026 revenue guidance, projecting growth for 2027; however, the lack of an official code has led to lowered revenue and EPS estimates for 2027 and 2028, reflecting a pessimistic outlook on the company's future.
- Price Target Cut: BofA slashed Inspire's stock price target from $53 to $39, indicating concerns over the company's future profitability, especially given the significant risks associated with the absence of a stable coding pathway.
- Market Reaction: Following BofA's downgrade, Inspire's stock fell in premarket trading, reflecting investor concerns about the company's outlook, particularly with the potential delay in obtaining official coding until 2028 or later.
See More
